Earnings ·
Black Diamond Therapeutics reports Q3 net loss of $10.0M and updates silevertinib Phase 2 data
BDTXBlack Diamond Therapeutics, Inc.
Black Diamond Therapeutics reported a net loss of $10.0 million for the third quarter ended September 30, 2026, compared to an $8.5 million loss in the prior year period. The company disclosed cash and investments of $102.0 million, sufficient to fund operations into late 2028. R&D expenses were $7.0 million, while G&A costs rose to $5.1 million due to IP-related expenses. The filing also highlighted updated Phase 2 results for silevertinib in frontline NSCLC patients with EGFR non-classical mutations, showing a 60% overall response rate and an 86% CNS objective response rate in patients with untreated brain metastases. FDA feedback supports a pivotal Phase 3 trial planned to initiate in the second quarter of 2027. Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies targeting families of oncogenic mutations.